Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

India's Third Giant Leap

This Leap Could Potentially Generate Gains
Far Bigger than Anything We Have Seen in Our Lifetimes




**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
**By submitting your email address, you also sign up for Profit Hunter, a Free-for-life newsletter from Equitymaster,
which offers the most profitable investing ideas in India.


AD

ALEMBIC PHARMA Share Price    (APLL)

Here is the latest stock price and chart of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.

REFRESH
Live BSE Quotes Feb 1, 2023 03:31:00 PM
Price (Rs)545.00 Open (Rs) 550.00 High (Rs) 554.75 Low (Rs) 535.55
% Change1.28 Volume 1,625 Value (Rs) 885,625 52-Week H/L 792.30 / 532.70
Live NSE Quotes Feb 1, 2023 3:29:49 PM
Price (Rs)544.10 Open (Rs) 540.95 High (Rs) 554.20 Low (Rs) 535.05
% Change1.09 Volume 39,032 Value (Rs) 21,256,827 52-Week H/L 792.90 / 532.00
Change
1 Day
1.28%		1 Month
-4.25%		3 Months
-5.78%		1 Year
-28.49%		5 Years (CAGR)*
-0.19%		10 Years (CAGR)*
21.75%

* Compound Annual Growth Rate

Valuation
EPS (Rs)* 14.39 P/E Ratio (x) 37.87 Market Cap (Rs m) 107,126.89 P/BV (x) 2.07 Dividend Yield (%) 1.83
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
Loading...
  
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new
Charts by TradingView

ALEMBIC PHARMA Share Price Today:

ALEMBIC PHARMA last traded price was up 1.3% to Rs 545.0 on the BSE. On the NSE, ALEMBIC PHARMA last traded price was up 1.1% to Rs 544.1. The total volume of shares traded was 0.0 m.

Overall, the broader S&P BSE HEALTHCARE Index was down by 0.3%. And the benchmark S&P BSE SENSEX was at 59,708.1 (up 0.3%).

Over the last 30 days, the ALEMBIC PHARMA share price is down 4.9%. And over the last one year, ALEMBIC PHARMA share price is down 28.0%.

The current market capitalisation of ALEMBIC PHARMA stands at Rs 107,126.89 m. For more information, check out the list of top 100 companies in India in terms of market cap.

As of December 2022, company promoters held 69.61% stake in ALEMBIC PHARMA, with no shares having been pledged. To know more, check out the latest shareholding pattern of ALEMBIC PHARMA.


What else is happening in the markets today? Dig in...


FAQs on ALEMBIC PHARMA

What is the ALEMBIC PHARMA share price today?

The last traded price of ALEMBIC PHARMA was Rs 545.0 on the BSE, up 1.3% over the previous close. On the NSE, ALEMBIC PHARMA last traded price was up 1.1% at Rs 544.1.

What is the market cap of ALEMBIC PHARMA?

The current market capitalisation of ALEMBIC PHARMA stands at Rs 107,127 m.

What is the Earnings per share (EPS) of ALEMBIC PHARMA?

ALEMBIC PHARMA had an EPS of Rs 14.4 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 6.9.

What is the PE Ratio and PB Ratio of ALEMBIC PHARMA?

At the current price of Rs 545.0, ALEMBIC PHARMA trades at a PE ratio of 37.87 while its PB ratio stands at 2.07.

What is the Dividend Yield of ALEMBIC PHARMA?

For the financial year 2022, ALEMBIC PHARMA declared dividend amounting to Rs 10.0 per share. At the current price of Rs 545.0, this results in a dividend yield of 1.8%.


Today's Market

Sensex Today Rallies 500 Points ahead of Union Budget | Adani Group Stocks Extend Fall | ICICI Bank & Tata Steel Top Gainers Sensex Today Rallies 500 Points ahead of Union Budget | Adani Group Stocks Extend Fall | ICICI Bank & Tata Steel Top Gainers(10:30 am)

Asian share markets advanced today following a rally overnight in US shares on signs of cooling inflation. This encouraged risk appetite ahead of the Federal Reserve's meeting.

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.